Steven Marc Massey

US Patent:

7915424, Mar 29, 2011

Filed:

Mar 9, 2005

Appl. No.:

10/598512

Inventors:

Francisco Javier Agejas-Chicharro - Madrid, ES
Bruce Anthony Dressman - Indianapolis IN, US
Jose Antonio Martinez Perez - Madrid, ES
James Allen Monn - Indianapolis IN, US
Mohammad Sadegh Zia-Ebrahimi - Indianapolis IN, US
Sonia Gutierrez Sanfeliciano - Madrid, ES
Steven Marc Massey - Indianapolis IN, US
Steven Scott Henry - New Palestine IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

C07D 211/78

US Classification:

546286, 546348, 546287, 546315, 546345

Abstract:

The present invention is directed toward pyridyl derivatives of formula (I) as antagonists of the mGlu5 receptor. As such the compounds may be useful for treatment or prevention of disorders remedied by antagonism of the mGlu5 receptor, wherein Ar is phenyl or napthyl each of which may be substituted by one or more C-Calkyl, C-Calkoxy, C-Cacyl, halo, amino, nitro, cyano, hydroxy, C-Cacylamino, C-Calkylsulfonylamino, mono-, di- or trifluorinated C-Calkyl, substituents which may be the same or different and may bear a CONH, CONHCH, CON(CH), COH, COCH, OCF, CHNHCOCH, CHNH, CHN(CH), CHCN, CHOH, CHNHSOCH, CHN(CH)(CH)CN, CHN(CH)CH(CH), CHNHCH(CH), CHNH(CH)CH, CHNHCOR, CHNHCHCH, CHNHCHNHCOC(CH), or N(S(O)CH)substituent; Ris hydrogen, halo, R, CN, C(NOH)R, C(NO—R)R, (CH)COR, (CH)OR, COR, CF, SR, S(O)R, S(O)R, COCHCOR, NHSOR, NHCOR, C(NOR)NH, CHOCOR, (CH)NH, CON(CH)(CH)NHCOR, COR, CONH, CSNH, C(NH)NHOR, (CH)N(CH), or CONHNHCOR; Ris 1,2-ethenediyl or 1,2-ethynediyl; Ris hydrogen or C-Calkyl; Ris C-Calkyl; and n is 0, 1, 2, 3 or 4; or a pharmaceutically acceptable salt thereof, or an N-oxide thereof.

US Patent:

20040116489, Jun 17, 2004

Filed:

Dec 8, 2003

Appl. No.:

10/467429

Inventors:

Steven Massey - Indianapolis IN, US
James Monn - Indianapolis IN, US
Matthew Valli - Zionsville IN, US
Lourdes Prieto - Madrid, ES

International Classification:

A61K031/423
A61K031/41
A61K031/325
A61K031/198

US Classification:

514/376000, 514/381000, 514/484000, 514/566000

Abstract:

The present invention provides novel compounds that affect certain excitatory amino acid receptors, and are useful in the treatment of neurological disorders and psychiatric disorders.

US Patent:

20040176459, Sep 9, 2004

Filed:

Dec 10, 2003

Appl. No.:

10/480517

Inventors:

Ana Melendo - Madrid, ES
Alfonso De Dios - Madrid, ES
Carmen Dominguez-Fernandez - Madrid, ES
Luisa Martin-Cabrejas - Madrid, ES
Jose Martin - Madrid, ES
Carlos Salgado - Madrid, ES
Concepcion Pedregal-Tercero - Madrid, ES
Rafael Ferritto Crespo - Madrid, ES
Marc Herin - Perwez, BE
Maria Martinez-Grau - Madrid, ES
Steven Massey - Indianapolis IN, US
James Monn - Indianapolis IN, US
Matthew Valli - Zionsville IN, US

International Classification:

A61K031/198
C07C229/28

US Classification:

514/566000, 562/501000

Abstract:

This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.

US Patent:

20040248963, Dec 9, 2004

Filed:

Apr 30, 2004

Appl. No.:

10/494189

Inventors:

Ana Bueno Melendo - Madrid, ES
Alfonso De Dios - Madrid, ES
Carmen Dominguez-Fernandez - Madrid, ES
Mark Herin - Perwez, BE
Luisa Martin-Cabrejas - Madrid, ES
Jose Martin - Madrid, ES
Maria Martinez-Grau - Madrid, ES
Steven Massey - Indianapolis IN, US
James Monn - Indianapolis IN, US
Carlos Montero Salgado - Madrid, ES
Concepcion Pedregal-Tercero - Madrid, ES
Matthew Valli - Zionsville IN, US

International Classification:

C07D317/08
A61K031/4035
A61K031/195

US Classification:

514/417000, 514/561000, 548/473000, 549/229000, 562/501000, 514/463000

Abstract:

This invention relates to synthetic excitatory amino acid prodrugs of formula (I) wherein the residues R, Rand Rare as defined in claim 1. The invention further relates to processes for the preparation of the compounds of formula (I), and to pharmaceutical compositions for the treatment of neurological and psychiatric disorders comprising said compounds.

US Patent:

20050009912, Jan 13, 2005

Filed:

Dec 5, 2002

Appl. No.:

10/496716

Inventors:

Ana Bueno Melendo - Madrid, ES
Alfonso De Dios - Madrid, ES
Carmen Dominguez-Fernandez - Madrid, ES
Rafael Ferritto Crespo - Madrid, ES
Jose Martin - Madrid, ES
Maria Martinez-Grau - Madrid, ES
Steven Massey - Indianapolis IN, US
James Monn - Indianapolis IN, US
Concepcion Pedregal-Tercero - Madrid, ES
Matthew Valli - Zionsville IN, US
Marc Herin - Perwez, BE

International Classification:

A61K031/198
C07C229/28

US Classification:

514561000, 514567000, 562433000, 562502000, 514443000

Abstract:

This invention relates to synthetic excitatory amino acid prodrugs of formula (I) wherein the residue R, Rand Rare aas defined in claim 1. The invention further relates to processes for the preparation of the compounds of formula (I), and to pharmaceutical compositions for the treatment of neurological and psychiatric disorders comprising said compounds.

US Patent:

62685074, Jul 31, 2001

Filed:

Aug 11, 2000

Appl. No.:

9/637143

Inventors:

Steven Marc Massey - Indianapolis IN
James Allen Monn - Indianapolis IN
Matthew John Valli - Zionsville IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

C07D48710
C07F 928
A61K 31415

US Classification:

5483014

Abstract:

Compounds of the formula ##STR1## in which R. sup. 1 and R. sup. 2 are as defined in the specification, and non-toxic metabolically labile ester and amides thereof are useful as modulators of metabotropic glutamate receptor function.

US Patent:

59589604, Sep 28, 1999

Filed:

May 13, 1998

Appl. No.:

9/078337

Inventors:

Steven Marc Massey - Indianapolis IN
James Allen Monn - Indianapolis IN
Matthew John Valli - Zionsville IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31415
C07D23502

US Classification:

514393

Abstract:

Compounds of the formula ##STR1## in which R. sup. 1 and R. sup. 2 are as defined in the specification, and non-toxic metabolically labile ester and amides thereof are useful as modulators of metabotropic glutamate receptor function.

US Patent:

56888260, Nov 18, 1997

Filed:

Nov 14, 1996

Appl. No.:

8/749140

Inventors:

Steven Marc Massey - Indianapolis IN
James Allen Monn - Indianapolis IN
Matthew John Valli - Indianapolis IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 3138
C07D30777

US Classification:

514443

Abstract:

Compounds for formula I ##STR1## in which X represents O, NR. sup. a, S, SO or SO. sub. 2 and R is as defined in the specification; and non-toxic metabolically labile esters or amides thereof; and pharmaceutically acceptable salts thereof are useful as modulators of metabotropic glutamate receptor function.